Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Gross Profit | -2.6M | 32.3% |
| Cost of Revenue | 2.6M | 8% |
| Operating expense | 4.4M | 14.5% |
| Net Income | -4.2M | 72.7% |
| EBITDA | -4.4M | 105.9% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 6.5M | 11.9% |
| Total Liabilities | 10M | 3.5% |
| Shares Outstanding | 50M | 206.7% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -4.3M | 18.5% |
| Cash from financing | 1.7M | 34.4% |
EPS
Financial Highlights for CERo Therapeutics in Q3 '24
Gross Profit stood at -2.6M, marking a -32.3% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 2.6M, a 8% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 4.4M, showing a -14.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -4.2M, showing a -72.7% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -4.4M, showing a -105.9% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
CERo Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures. A decline in EBITDA signals potential operational challenges or increased costs.
